<p>Therapeutic peptides and proteins form higher-order structures (HOS) including oligomeric forms in formulation, critical for drug efficacy, safety, and stability. To quickly assess protein oligomerization, dynamic light scattering (DLS) was applied to measure a series of protein standards with molecular weight (MW) range of 1.3–660&#xa0;kDa, yielding translational diffusion coefficients (<i>D</i><sub>dls</sub>), which were corrected to <i>D</i><sub>corr</sub> using water diffusion data. A correlation between <i>D</i><sub>corr</sub> and protein monomeric MW, representing their hydrodynamic MW (MW<sub>hd</sub>), was established as <InlineEquation ID="IEq1"> <EquationSource Format="TEX">\(\mathbf{l}\mathbf{o}\mathbf{g}({{\varvec{D}}}_{\mathbf{c}\mathbf{o}\mathbf{r}\mathbf{r}})=-0.428\mathbf{l}\mathbf{o}\mathbf{g}\left({\mathbf{M}\mathbf{W}}_{\mathbf{h}\mathbf{d}}\right)-5.412\)</EquationSource> <EquationSource Format="MATHML"><math> <mrow> <mi mathvariant="bold">l</mi> <mi mathvariant="bold">o</mi> <mi mathvariant="bold">g</mi> <mrow> <mo stretchy="false">(</mo> <msub> <mrow> <mi mathvariant="bold-italic">D</mi> </mrow> <mrow> <mi mathvariant="bold">c</mi> <mi mathvariant="bold">o</mi> <mi mathvariant="bold">r</mi> <mi mathvariant="bold">r</mi> </mrow> </msub> <mo stretchy="false">)</mo> </mrow> <mo>=</mo> <mo>-</mo> <mn>0.428</mn> <mi mathvariant="bold">l</mi> <mi mathvariant="bold">o</mi> <mi mathvariant="bold">g</mi> <mfenced close=")" open="("> <msub> <mrow> <mi mathvariant="bold">M</mi> <mi mathvariant="bold">W</mi> </mrow> <mrow> <mi mathvariant="bold">h</mi> <mi mathvariant="bold">d</mi> </mrow> </msub> </mfenced> <mo>-</mo> <mn>5.412</mn> </mrow> </math></EquationSource> </InlineEquation>. This DLS/MW<sub>hd</sub> model was subsequently applied to therapeutic protein formulations with monomeric MW ranging from 3.8 to 149&#xa0;kDa. The resulting MW<sub>hd</sub> values were several-fold greater than the corresponding monomeric MW of the glucagon-like peptide-1/2 (GLP-1/2) analogs, insulin analogs, and the monoclonal antibodies (mAbs) infliximab and bevacizumab, indicating varying degrees of oligomerization. The observed oligomerization states were largely consistent with those reported in literature. For insulin and mAb oligomers, pseudo-spherical diffusion coefficients (<i>D</i><sub>s</sub>) back calculated from the oligomer MW agreed within 6% of experimental <i>D</i><sub>corr</sub> values, except for the insulin dimer. Incorporation of Perrin’s anisotropic correction reduced insulin dimer discrepancy from 9 to 5%. Overall, the established MW<sub>hd</sub> model, incorporating a larger exponent of 0.428 that accounts for protein anisotropy, provides a rapid, non-invasive method to factually assess protein oligomerization in as-is formulations, aiding drug development and quality control. Minor discrepancies relative to size exclusion chromatograph (SEC) or prior biophysical studies may arise from experimental differences in protein concentration, oligomeric equilibrium, pH, excipients or modeling assumptions, warranting further investigation.</p> Graphical Abstract <p></p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation

  • Jiaqi Lu,
  • Kang Chen

摘要

Therapeutic peptides and proteins form higher-order structures (HOS) including oligomeric forms in formulation, critical for drug efficacy, safety, and stability. To quickly assess protein oligomerization, dynamic light scattering (DLS) was applied to measure a series of protein standards with molecular weight (MW) range of 1.3–660 kDa, yielding translational diffusion coefficients (Ddls), which were corrected to Dcorr using water diffusion data. A correlation between Dcorr and protein monomeric MW, representing their hydrodynamic MW (MWhd), was established as \(\mathbf{l}\mathbf{o}\mathbf{g}({{\varvec{D}}}_{\mathbf{c}\mathbf{o}\mathbf{r}\mathbf{r}})=-0.428\mathbf{l}\mathbf{o}\mathbf{g}\left({\mathbf{M}\mathbf{W}}_{\mathbf{h}\mathbf{d}}\right)-5.412\) l o g ( D c o r r ) = - 0.428 l o g M W h d - 5.412 . This DLS/MWhd model was subsequently applied to therapeutic protein formulations with monomeric MW ranging from 3.8 to 149 kDa. The resulting MWhd values were several-fold greater than the corresponding monomeric MW of the glucagon-like peptide-1/2 (GLP-1/2) analogs, insulin analogs, and the monoclonal antibodies (mAbs) infliximab and bevacizumab, indicating varying degrees of oligomerization. The observed oligomerization states were largely consistent with those reported in literature. For insulin and mAb oligomers, pseudo-spherical diffusion coefficients (Ds) back calculated from the oligomer MW agreed within 6% of experimental Dcorr values, except for the insulin dimer. Incorporation of Perrin’s anisotropic correction reduced insulin dimer discrepancy from 9 to 5%. Overall, the established MWhd model, incorporating a larger exponent of 0.428 that accounts for protein anisotropy, provides a rapid, non-invasive method to factually assess protein oligomerization in as-is formulations, aiding drug development and quality control. Minor discrepancies relative to size exclusion chromatograph (SEC) or prior biophysical studies may arise from experimental differences in protein concentration, oligomeric equilibrium, pH, excipients or modeling assumptions, warranting further investigation.

Graphical Abstract